Quantcast

Latest Anorectics Stories

2014-09-24 23:02:01

The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer. New York, New York (PRWEB) September 24, 2014 Byetta lawsuits(http://www.byettalawsuit.com) and other product liability claims that allege incretin mimetic Type 2 diabetes medications caused patients to develop pancreatic cancer continue to move forward in U.S. courts, Bernstein Liebhard LLP...

2014-09-23 08:30:46

18-MC Well Tolerated by Subjects in Development Partner's Study SAN CARLOS, Calif., Sept. 23, 2014 /PRNewswire/ -- Savant HWP, Inc., a privately held drug development company, today confirmed the initiation of human safety testing of 18-MC, an experimental treatment for many forms of addiction. A single dose of 18-MC, administered as part of a double-blind, placebo-controlled human safety study conducted by Savant's South American partner, was well tolerated by healthy volunteers...

2014-09-17 08:29:46

- Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and prescribers perceive VIENNA, Sept. 17, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the presentation of compelling, quantitative data from a study of the cost and predictability of non-adherence in type 2 diabetes therapies at the 50(th) Annual Meeting of the European Association for the Study of Diabetes (EASD). In a poster session today, Christian...

2014-09-15 08:29:16

PHILADELPHIA, September 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the...

contrave
2014-09-12 05:31:01

John Hopton for redOrbit.com - Your Universe Online The Food and Drug Administration (FDA) has approved the weight loss pill Contrave, a medication that will be used to treat obese adults in conjunction with a controlled diet and exercise. It is the third such drug to be approved since 2012, although its predecessors have not sold well and all have considerable potential side effects. An FDA statement advises that Contrave, which works by decreasing appetite, is approved for use in...

2014-09-11 16:27:32

Colorado and Washington experience surges in marijuana tests positivity rate, but data suggests state legalization of recreational marijuana may not be sole driver of increases MADISON, N.J., Sept. 11, 2014 /PRNewswire/ -- The percentage of positive drug tests among American workers has increased for the first time in more than a decade, fueled by a rise in marijuana and amphetamines, according to an analysis of 8.5 million urine, oral fluid and hair workplace drug test results...

2014-09-11 08:27:41

New Medication for Obese Adults, or Overweight Adults with at Least One Weight-Related Comorbid Condition DEERFIELD, Ill., and LA JOLLA, Calif., Sept. 11, 2014 /PRNewswire/ -- Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. (Nasdaq: OREX) jointly announced today that the U.S. Food and Drug Administration (FDA) has approved Contrave® (naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for...

2014-09-08 08:30:08

IADSA to Support ABC-AHP-NCNPR Botanical Adulterants Program, International Herbal Quality Control Initiative AUSTIN, Texas, Sept. 8, 2014 /PRNewswire-USNewswire/ -- The International Alliance of Dietary/Food Supplement Associations (IADSA) has endorsed the ABC-AHP-NCNPR Botanical Adulterants Program, an international consortium of nonprofit organizations, analytical laboratories, industry members, professional scientists, and others that advises industry, health professionals, and...

2014-09-02 08:29:50

- Patent Protection for NB32 for Treating Insulin Resistance - SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S. Patent and Trademark Office (PTO) has issued a patent related to NB32, the Company's investigational medication being evaluated for weight loss. NB32 is a fixed-dose combination of naltrexone sustained release (SR) and bupropion SR. U.S. Patent No. 8,815,889 claims methods for treating insulin resistance...

2014-08-30 23:02:07

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication. New York, New York (PRWEB) August 30, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in U.S. courts, Bernstein Liebhard LLP reports. According to a statement issued by AstraZeneca PLC on July 31, 2014, Byetta and Bydureon (an extended-release...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related